Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Spindler, Karen Lise Garm ^a,b   Pallisgaard, Niels ^a   Andersen, Rikke Fredslund ^a   Brandslund, Ivan ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; CIRCULATING FREE DNA; DNA; EDETIC ACID; GEMCITABINE; IRINOTECAN; PEMETREXED; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; TISSUE LEVEL; AGED; BLOOD; CLINICAL TRIAL; COLON; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS; RECTUM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; COLON; COLORECTAL NEOPLASMS; DNA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); RECTUM;

EID: 84927615702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108247     Document Type: Article

References (32)

1. Mandel P, Metais P. CR Seances Soc Biol Fil 1948; 142:241-3. PMID: 18875018
2. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, et al. (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells Cancer Res 61:1659-65. PMID: 11245480
3. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102:16368-73. PMID: 16258065
4. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313:139-42. PMID: 11694251
5. Gormally E, Caboux E, Vineis P, Hainaut P (2007) Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635:105-17. PMID: 17257890
6. Su YH, Wang M, Brenner DE, Norton PA, Block TM (2008) Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci 1137:197-206. doi: 10.1196/annals.1448.027 PMID: 18837947
7. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-50 PMID: 837366
8. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, et al. (2012) Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 7 (11).
9. van der Vaart M, Pretorius PJ (2010) Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 43:26-36. doi: 10.1016/j.clinbiochem.2009.08.027 PMID: 19747472
10. De Mattos-Arruda L, Olmos D, Tabernero J (2011) Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer.Future Oncol 7:1385-97. doi: 10.2217/fon.11.122 PMID: 22112315
11. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A (2012) Quantitative cell free DNA, KRAS and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18:1177-85., doi: 10.1158/1078-0432.CCR-11-0564 PMID: 22228631
12. Spindler KL, Sorensen M, Pallisgaard N, Andersen R, Havelund BM, et al. (2013) Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol; 52:963-70. doi: 10.3109/ 0284186X.2013.776175 PMID: 23514584
13. Spindler K-LG, Pallisgaard N, Andersen RF, Pløen J, Jakobsen A (2013) Pemetrexed and Gemcitabine for Chemotherapy Refractory Colorectal Cancer-Results of a Phase II and Translational Research Study. Journal of Cancer Therapy, vol 4, s. 44-50.
14. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, et al. (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med Mar 13. [Epub ahead of print]
15. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-40. doi: 10.1038/ nature11219 PMID: 22722843
16. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-6. doi: 10.1038/ nature11156 PMID: 22722830
17. Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, et al. (2010) Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 46:2781-7. doi: 10.1016/j.ejca.2010.05.022 PMID: 20580219
18. Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P (2013) Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem 433:227-34. doi: 10.1016/j.ab.2012.06.018 PMID: 22750103
19. Steffensen KD, Waldstrom M, Grove A, Lund B, Pallisgard N, Jakobsen A (2011) Improved classification of epithelial ovarian cancer: results of 3 danish cohorts. Int J Gynecol Cancer 21:1592-600. doi: 10.1097/IGC.0b013e31822a0f6b PMID: 21926912
20. Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF (2009) The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 20: 879-84. doi: 10.1093/annonc/mdn712 PMID: 19179548
21. Qi J, Qian C, Shi W, Wu X, Jing R, et al (2013) Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer. Clin Biochem
22. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, et al. (2006) Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12:6985-8. PMID: 17145818
23. Danese E, Montagnana M, Minicozzi AM, De Matteis G, Scudo G, et al. (2010) Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers.Clin Chem Lab Med 48:
24. Boni L, Cassinotti E, Canziani M, Dionigi G, Rovera F (2007) Free circulating DNA as possible tumour marker in colorectal cancer. Surg Oncol. 16:S29-31. PMID: 18024018
25. Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, et al. (2011) Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol 18:2461-8. doi: 10.1245/s10434-011-1638-y PMID: 21416156
26. Nygaard AD, Holdgaard PC, Spindler KL, Pallisgaard N, Jakobsen A (2013), The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. Br J Cancer Nov 14. doi: 10.1038/bjc.2013.705 [Epub ahead of print]
27. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985-90. doi: 10.1038/nm.1789 PMID: 18670422
28. Mora J, Urgell E, Farré A, Comas L, Montserrat E (2006) Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. Clin Chem 52:1448-9. PMID: 16798981
29. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, et al. (2000) Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 92:918-23. PMID: 10841827
30. Marchese R, Muleti A, Pasqualetti P, Bucci B, Stigliano A, et al. (2006) Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 32:171-7. PMID: 16552337
31. Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, et al. (2009) Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 15:4508-13 doi: 10.1158/1078-0432.CCR-08-3179 PMID: 19549774
32. Spindler KL, Pallisgaard N, Andersen RF, Ploen J, Jakobsen A (2014) Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients-a phase II and translational research study. Anticancer Res. Feb; 34(2):845-50. PMID: 24511021